Table 2 Progression-Free Survival and Overall Survival, calculated from the date of PET-2, by patient characteristics at diagnosis relapse or progression and by response to salvage therapy: Univariable analysis.

From: Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

Predictive Factors

PFS

OS

HR (CI 95%)

P

HR (CI 95%)

P

Age at diagnosis, median (range)

1 (0.99–1.02)

0.7836

1.03 (1–1.07)

0.0421

 < 45 years

1

 

1

 

 ≥ 45 years

1.2 (0.75–1.93)

0.4832

2.53 (1.13–5.65)

0.0238

Sex

 Male

1

 

1

 

 Female

0.85 (0.56–1.31)

0.4681

0.45 (0.19–1.08)

0.0724

Histology

 Nodular sclerosis

1

 

1

 

 Other

0.81 (0.5–1.3)

0.377

2.23 (1–4.97)

0.0506

Ann Arbor Stage

 IIB

1

 

1

 

 III

1.07 (0.6–1.9)

0.8272

1.13 (0.36–3.56)

0.8371

 IV

0.94 (0.58–1.54)

0.8101

1.23 (0.48–3.13)

0.6631

B Symptoms

 No

1

 

1

 

 Yes

0.96 (0.6–1.54)

0.876

0.75 (0.32–1.76)

0.5087

IPS

 0–1

1

 

1

 

 > 1

1.07 (0.61–1.9)

0.8068

1.03 (0.35–3)

0.9620

Large nodal mass

 <5 cm

1

 

1

 

 5–7 cm

0.83 (0.42–1.61)

0.5728

0.16 (0.02–1.24)

0.0794

 7–10 cm

0.96 (0.54–1.71)

0.8996

0.5 (0.15–1.63)

0.2515

 >10 cm

1.19 (0.67–2.11)

0.5628

1.21 (0.47–3.14)

0.693

 Undefined

1 (0.38–2.61)

0.9962

1.13 (0.24–5.26)

0.8721

Leukocytes

 < 15 × 103/μL

1

 

1

 

 ≥ 15 × 103/μL

0.63 (0.41–0.98)

0.0385

0.17 (0.05–0.58)

0.0044

Neutrophils

1 (0.95–1.04)

0.8857

0.9 (0.8–1.01)

0.0836

Lymphocytes

 ≥ 0.6 × 103/μL

1

 

1

 

 < 0.6 × 103/μL

3.19 (1.63–6.23)

0.0007

1.9 (0.57–6.38)

0.2985

Monocytes

 < 0.5 × 103/μL

1

 

1

 

 ≥ 0.5 × 103/μL

0.71 (0.39–1.27)

0.2447

0.35 (0.14–0.87)

0.0241

NLR

 ≤ 6

1

 

1

 

 > 6

1.37 (0.87–2.15)

0.1732

1.13 (0.5–2.59)

0.7680

LMR

 ≤ 2

1

 

1

 

 > 2

0.85 (0.53–1.37)

0.5013

1.28 (0.54–3.02)

0.5710

Hemoglobin

 ≥ 10.5 g/dL

1

 

1

 

 < 10.5 g/dL

0.84 (0.51–1.41)

0.5164

0.63 (0.22–1.85)

0.4001

TMTV ≤ 192

1

 

1

 

TMTV > 192

1.13 (0.69–1.85)

0.6285

1.53 (0.58–4.09)

0.3920

TLG ≤ 58

1

 

1

 

TLG > 58

1.37 (0.19–9.88)

0.7553

25074972.47 (0-Inf)

0.9982

  1. PFS Progression-free Survival from the date of PET-2, OS Overall Survival from the date of PET-2, HR Hazard Risk, CI Confidence Interval, IPS International Prognostic Score, NLR Neutrophils/Lymphocytes Ratio, LMR Lymphocytes/Monocytes Ratio, TMTV Total Metabolic Tumor Volume, TLG total lesion glycolysis.
Back to article page